The Comparative Safety of Various Intravenous Iron Preparations in Chronic Kidney Disease Patients
Open Access
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis Ltd in Renal Failure
- Vol. 30 (6), 629-638
- https://doi.org/10.1080/08860220802134631
Abstract
The relative safety of parenteral iron preparations is a controversial issue in the management of anemia in chronic kidney disease (CKD), as direct head-to-head comparative trials are lacking. In this study, patients of CKD were randomized to receive intravenous low molecular weight iron dextran (ID), sodium ferrigluconate complex (SFGC), and iron sucrose (IS) at doses and infusion rates recommended by the product manufacturer. One time test dose was used only for ID and SFGC. A total of 2,980 injections (n = 339) of i.v. iron was given, and 49 patients (14.45% per patient) and a total of 56 adverse events (1.88% per infusion) were noted. Odds ratios (OR) of serious adverse drug events (ADE; i.e., death, anaphylaxis, or suspected immuno-allergic events) per patient was not significant between ID vs. SFGC (3.566) and SFGC vs. IS (2.129), whereas that between ID vs. IS (7.594) was highly significant (p = 0.034). OR of serious ADE exposure was significantly higher in ID vs. SFGC (OR = 5.670, p = 0.0147) and ID vs. IS (OR = 7.799, p < 0.001). No significant difference was seen between the three groups in terms of non-serious ADEs. Drug discontinuation occurred significantly more often with ID. One patient who developed anaphylactoid reaction with SFGC and ID tolerated iron sucrose well.Keywords
This publication has 24 references indexed in Scilit:
- Symposium on the Definition and Management of Anaphylaxis: Summary reportJournal of Allergy and Clinical Immunology, 2005
- Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimensKidney International, 2004
- Safety of Iron Sucrose in Hemodialysis Patients Intolerant to Other Parenteral Iron ProductsNephron Clinical Practice, 2004
- Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patientsKidney International, 2003
- Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextranKidney International, 2002
- Efficacy and Safety of Iron Sucrose for Iron Deficiency in Patients With Dialysis-Associated Anemia: North American Clinical TrialAmerican Journal of Kidney Diseases, 2001
- IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000American Journal of Kidney Diseases, 2001
- Adverse Events in Chronic Hemodialysis Patients Receiving Intravenous Iron Dextran – A Comparison of Two ProductsAmerican Journal of Nephrology, 2000
- The safety of intravenous iron dextran in hemodialysis patientsAmerican Journal of Kidney Diseases, 1996
- Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitorJournal of Allergy and Clinical Immunology, 1994